The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression
Abstract
CONTEXT: Proton pump inhibitors (PPIs) and H(2) receptor antagonists (H(2)RAs) have become the mainstay of therapy in acid-related upper gastrointestinal disorders. There have been concerns raised about the possible association of PPIs with enteric infections. OBJECTIVE: We conducted a systematic review to evaluate any association between acid suppression and enteric infection. We also assessed differences between types of enteric infections and the type of acid suppression. DATA SOURCES: Electronic searches of MEDLINE (1966-2005), EMBASE (1988-2005), and CINAHL (1982-2005) were undertaken using a combination of subject headings and text words related to PPI therapy, H(2)RAs, and enteric infections. STUDY SELECTION: All observational studies were eligible, including cross-sectional, case control, and cohort studies that evaluated risk of enteric infection associated with antisecretory therapy. Eligibility assessment was made by two independent researchers. DATA EXTRACTION: Information on study design, patient population, type of acid suppression, type of infection, and outcomes was collected. The odds ratio (OR) of taking acid suppression therapy in cases and controls was calculated and results were synthesized using a random effects model (DerSimonian and Laird, Stats direct version 2.4.4). DATA SYNTHESIS: A total of 12 papers evaluating 2,948 patients with Clostridium difficile were included in the review. There was an increased risk of taking antisecretory therapy in those infected with C. difficile (pooled OR 1.94, 95% CI 1.37-2.75). There was significant heterogeneity between the studies (P= 0.0006) that was not explained by planned subgroup analysis. The association was greater for PPI use (OR 1.96, 95% CI 1.28-3.00) compared with H(2)RA use (OR 1.40, 95% CI 0.85-2.29). A total of six studies evaluated Salmonella, Campylobacter, and other enteric infections in 11,280 patients. There was an increased risk of taking acid suppression in those with enteric infections (OR 2.55, 95% CI 1.53-4.26). There was significant heterogeneity between the studies (P < 0.0001) that was not explained by subgroup analysis. The association was greater for PPI use (OR 3.33, 95% CI 1.84-6.02) compared with H(2)RA use (OR 2.03, 95% CI 1.05-3.92). CONCLUSION: There is an association between acid suppression and an increased risk of enteric infection. Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Supporting the importance of such mechanisms, a growing body of evidence has linked acid-reducing medications such as proton pump inhibitors and histamine H2 antagonists, with increased risk of enteric infections such as clostridium difficile[248–250] and profound alterations”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [249]
In the citing paper
“PPIs can influence the onset of enteric infections, resulting in an increased risk of Clostridium difficile infection (CDI), as well as Salmonella, Campylobacter and diarrheagenic Escherichia coli (E. coli)[110-113].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [112]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M., Michaud, S., Bourgault, A., Nguyen, T., Frenette, C. H., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,962
Dial, S. (2005) · JAMA · doi:10.1001/jama.294.23.2989 · Cited by 954
Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
Laheij, R. J. F. (2004) · JAMA · doi:10.1001/jama.292.16.1955 · Cited by 879
Muto, C. A., Pokrywka, M., Shutt, K. A., Mendelsohn, A. B., Nouri, K., Posey, K., Roberts, T. L., Croyle, K. S., Krystoflak, S., Patel-Brown, S., et al. (2005) · Infection Control and Hospital Epidemiology · doi:10.1086/502539 · Cited by 619
Dial, S. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040876 · Cited by 577
Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding
Barkun, A. N., Bardou, M., Marshall, J. K., & for the Nonvariceal Upper GI Bleeding Consensus Conference Group* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00012 · Cited by 540
Research works printed but not linked: 4
- Laheij RJ, JAMA, 2004, 1955
- 10.1001/archinte.146.1.95 · DOI
- Gillis C, 2006, Gastroenterol, 20, 191
- Rostom A, 2002, Cochrane Database Syst Rev, 4
Cited by
Sorted by citations
Items 201–300 of 631
Masood, U., Sharma, A., Bhatti, Z., Carroll, J., Bhardwaj, A., Sivalingam, D., & Dhamoon, A. S. (2018) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/0046958018759116 · Cited by 36
Sun, Q., Wang, H., Sun, S.-D., Zhang, X., & Zhang, H. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i17.2110 · Cited by 36
RetractedProton pump inhibitors and gastroenteritis
Hassing, R., Verbon, A., de Visser, H., Albert Hofman, D., & Stricker, B. H. C. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0136-8 · Cited by 37
Horvath, A., Leber, B., Feldbacher, N., Steinwender, M., Komarova, I., Rainer, F., Blesl, A., & Stadlbauer, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-59550-x · Cited by 37
Godman, B., Malmström, R. E., Bennie, M., Sakshaug, S., Burkhardt, T. H., Campbell, S., Garuolienè, K., Schwabe, U., Vončina, L., & Gustafsson, L. L. (2011) · Reviews in Health Care · doi:10.7175/rhc.55315-16 · Cited by 34
Huang, K.-W., Kuan, Y., Luo, J., Lin, C., Liang, J., & Kao, C. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.04.016 · Cited by 34
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons
Fisher, L., & Fisher, A. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0519-y · Cited by 37
Koo, S., Deng, J., Ang, D., Hsiang, J. C., Ls, L., Aazmi, M. S., Mohamed, E., Yang, H., Yap, S., Teh, L. K., et al. (2018) · Singapore Medical Journal · doi:10.11622/smedj.2018152 · Cited by 33
Vinke, P., Wesselink, E., van Orten-Luiten, A. C. B., & van Norren, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010323 · Cited by 33
Acid suppressing therapy as a risk factor forCandidaesophagitis
Daniell, H. (2015) · Diseases of the Esophagus · doi:10.1111/dote.12354 · Cited by 32
Saini, S. D. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1684 · Cited by 32
A review of stress‐related mucosal disease
Monnig, A. A., & Prittie, J. E. (2011) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/j.1476-4431.2011.00680.x · Cited by 31
Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD
Holtmann, G., Bigard, M., Malfertheiner, P., & Pounder, R. E. (2011) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-011-9489-y · Cited by 32
Teramura-Grönblad, M., Bell, J. S., Pöysti, M. M., Strandberg, T. E., Laurila, J., Tilvis, R. S., Soini, H., & Pitkälä, K. H. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.03.003 · Cited by 31
Opinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units
Eastwood, G. M., Litton, E., Bellomo, R., Bailey, M., Festa, M., Beasley, R. W., & Young, P. J. (2014) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01468-0 · Cited by 31
Knorr, J. P., Sjeime, M., Braitman, L. E., Jawa, P., Zaki, R. F., & Ortiz, J. (2013) · Transplantation · doi:10.1097/01.tp.0000436100.65983.10 · Cited by 31
Effectiveness and Safety of Histamine H2 Receptor Antagonists: An Umbrella Review of Meta‐Analyses
Meng, R., Chen, L., Zhang, M., Cai, W., Yin, S., Fan, Y., Zhou, T. Y., Huang, Y., & He, G. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2147 · Cited by 30
Orally Administered Drugs and Their Complicated Relationship with Our Gastrointestinal Tract
Bashiardes, S., & Christodoulou, C. (2024) · Microorganisms · doi:10.3390/microorganisms12020242 · Cited by 36
Saini, S. D., Fendrick, A. M., & Scheiman, J. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04707.x · Cited by 30
A safety review of proton pump inhibitors to treat acid-related digestive diseases
Savarino, E. V., Marabotto, E., Zentilin, P., Furnari, M., Bodini, G., Pellegatta, G., Lorenzon, G., Coletta, M. D., Ghisa, M., Coppo, C., et al. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1497155 · Cited by 30
Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer
Paz, M. F. C. J., de Alencar, M. V. O. B., de Lima, R. M. P., Sobral, A. L. P., do Nascimento, G. T. M., dos Reis, C. A., Coêlho, M. D. P. S. D. S., do Nascimento, M. L. L. B., Júnior, A. L. G., Machado, K. D. C., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3457890 · Cited by 31
Impact of non-antibiotic drugs on the human intestinal microbiome
Bastard, Q. L., Berthelot, L., Soulillou, J., & Montassier, E. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1952075 · Cited by 31
Finke, M., Boven, A., Vlieghe, E., Engstrand, L. G., Orsini, N., & Brusselaers, N. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106488 · Cited by 29
de Jong, H. J. I., Korevaar, J. C., van Dijk, L., Voogd, E., van Dijk, C. E., & van Oijen, M. G. H. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003044 · Cited by 29
Variables Associated with Stress Ulcer Prophylaxis Misuse: A Retrospective Analysis
Issa, I. A., Soubra, O., Chmaisse, H. N., & Soubra, L. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2104-9 · Cited by 32
Hip Fracture and Proton Pump Inhibitor Therapy: Balancing the Evidence for Benefit and Harm
Moayyedi, P., & Cranney, A. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02031.x · Cited by 29
Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study
Min, Y. W., Kang, D., Shin, J., Kang, M., Park, J. K., Lee, K. H., Lee, J. K., Lee, K. T., Rhee, P., Kim, J. J., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15466 · Cited by 28
Pranata, R., Huang, I., Lawrensia, S., Henrina, J., Lim, M. A., Lukito, A. A., Kuswardhani, R. A. T., & Wibawa, I. D. N. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00263-x · Cited by 28
Clinical presentation and outcomes of non-typhoidal Salmonella infections in patients with cancer
Mori, N., Szvalb, A. D., Adachi, J. A., Tarrand, J. J., & Mulanovich, V. E. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06710-7 · Cited by 28
Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship
Dutta, A. K., Jain, A. K., Jearth, V., Mahajan, R., Panigrahi, M. K., Sharma, V., Goenka, M. K., Kochhar, R. K., Makharia, G. K., Reddy, D. N., et al. (2023) · Indian Journal of Gastroenterology · doi:10.1007/s12664-023-01428-7 · Cited by 33
Does PPI therapy predispose to Clostridium difficile infection?
Pant, C., Madonia, P. N., & Minocha, A. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.128 · Cited by 28
Jensen, A. K., Simonsen, J., & Ethelberg, S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw860 · Cited by 28
Deprescribing Proton Pump Inhibitors in an Academic, Primary Care Clinic
Nallapeta, N. S., Reynolds, J. L., & Bakhai, S. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001317 · Cited by 27
Miyamoto, S., Kato, M., Matsuda, K., Abiko, S., Tsuda, M., Mizushima, T., Yamamoto, K., Ono, S., Kudo, T., Shimizu, Y., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.8040 · Cited by 27
Abuelkhair, M., Abdu, S., Godman, B., Fahmy, S., Malmström, R. E., & Gustafsson, L. L. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.90 · Cited by 27
Tran‐Duy, A., Vanmolkot, F. H. M., Joore, M. A., Hoes, A. W., & Stehouwer, C. D. A. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12634 · Cited by 26
Kim, J., Jeong, Y., Park, S.-J., Jin, H. Z., Lee, J. J., Ju, J. H., Ji, G. E., & Park, S. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa316 · Cited by 26
Flook, N. W., Moayyedi, P., Dent, J., Talley, N. J., Persson, T., Karlson, B. W., & Ruth, M. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.369 · Cited by 26
The management of Clostridium difficile infection
Williams, O. M., & Spencer, R. C. (2009) · British Medical Bulletin · doi:10.1093/bmb/ldp021 · Cited by 26
Stewart, D. B., & Hegarty, J. P. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.059709-0 · Cited by 26
A 32-Year-Old Woman With Chronic Abdominal Pain
Lacy, B. E. (2008) · JAMA · doi:10.1001/jama.2007.51-a · Cited by 26
Lanas, Á., Esplugues, J. V., Zapardiel, J., & Sobreviela, E. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5953 · Cited by 25
Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem
Kanno, T., & Moayyedi, P. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0732-3 · Cited by 26
Iron at the crossroads of host–microbiome interactions in health and disease
Choi, G., & Bessman, N. J. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02001-y · Cited by 28
The Incidence and Clinical Features ofClostridium difficileInfection; Single Center Study
Lee, J. H., Lee, S.-Y., Kim, Y. S., Park, S.-W., Park, S. W., Jo, S. Y., Ryu, S. H., Lee, J. H., Moon, J. S., Whang, D. H., et al. (2010) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2010.55.3.175 · Cited by 24
Fraeyman, J., Hal, G. F. V., Godman, B., & Beutels, P. (2013) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.12.88 · Cited by 24
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24
Gastric mucosal cracked and cobblestone‐like changes resulting from proton pump inhibitor use
Miyamoto, S., Kato, M., Tsuda, M., Matsuda, K., Muranaka, T., Abiko, S., Ono, M., Mizushima, T., Omori, S., Yamamoto, K., et al. (2016) · Digestive Endoscopy · doi:10.1111/den.12765 · Cited by 24
Use and Incidence of Adverse Effects of Proton Pump Inhibitors in Patients with Cystic Fibrosis
McCrory, B. E., Harper, H. N., & McPhail, G. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2125 · Cited by 24
Sharara, A. I., Chalhoub, J. M., Hammoud, N., Harb, A. H., Sarkis, F. S., & Hamadeh, G. N. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.10.012 · Cited by 23
Yuan, J., Zhang, C., Sparks, J. A., Malspeis, S., Tsoi, K. K., Kim, J. H., Fisher, B. A., Gao, F., Sumerlin, T. S., Liu, Y., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15834 · Cited by 23
Targeting the gut microbiome in the management of sepsis-associated encephalopathy
Barlow, B., Ponnaluri, S., Barlow, A., & Roth, W. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.999035 · Cited by 25
Controversies in the Treatment of Gastroesophageal Reflux Disease in Preterm Infants
Tipnis, N. A., & Tipnis, S. (2009) · Clinics in Perinatology · doi:10.1016/j.clp.2008.09.011 · Cited by 23
Park, S. W., Choi, A., Lee, H. J., Chung, H., Park, J. C., Shin, S. K., Lee, S. K., Lee, Y. C., Kim, J. E., & Lee, H. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12439 · Cited by 23
Practical considerations in the management of proton-pump inhibitors
Aguilera, L., de Prados, C. M. D. A., & Albillos-Martínez, A. (2015) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2015.3812/2015 · Cited by 23
Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease
Kung, Y.-M., Hsu, W., Wu, M., Wang, J., Liu, C., Su, Y.-C., Kuo, C., Kuo, F., Wu, D., & Wang, Y. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4830-5 · Cited by 23
Lenoir, C., Biali, M. E., Luthy, C., Grosgurin, O., Desmeules, J. A., & Rollason, V. (2019) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-019-00929-w · Cited by 23
Side Effects of Proton Pump Inhibitors: What are Patients’ Concerns?
Rameau, A., Andreadis, K., Bayoumi, A., Kaufman, M. W., & Belafsky, P. C. (2020) · Journal of Voice · doi:10.1016/j.jvoice.2020.01.018 · Cited by 23
Microbiote et probiotiques : impact en santé humaine
Coudeyras, S., & Forestier, C. (2010) · Canadian Journal of Microbiology · doi:10.1139/w10-052 · Cited by 36
Considerations for the Use of Proton-Pump Inhibitors in Older Adults
Desilets, A. R., Asal, N. J., & Dunican, K. C. (2012) · The Consultant Pharmacist · doi:10.4140/tcp.n.2012.114 · Cited by 23
Indications and safety of proton pump inhibitor drug use in patients with cancer
Triadafilopoulos, G., Roorda, A. K., & Akiyama, J. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.797961 · Cited by 23
Epidemiología de la infección por Clostridium difficile en España
Asensio, Á., & Martín, D. M. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.09.010 · Cited by 22
Clostridium difficile Infection: Yet Another Predictor of Poor Outcome in Cirrhosis
García–Tsao, G., & Surawicz, C. M. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.604 · Cited by 22
Clinical approach to severe Clostridium difficile infection: Update for the hospital practitioner
Pant, C., Sferra, T. J., Deshpande, A., & Minocha, A. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.04.009 · Cited by 21
Leonard, A., Ho, K. M., & Flexman, J. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02770.x · Cited by 21
Gao, W., Gulliford, M. C., Morgan, M., & Higginson, I. J. (2020) · BMC Family Practice · doi:10.1186/s12875-020-01127-8 · Cited by 21
Risk factors for campylobacteriosis in Australia: outcomes of a 2018–2019 case–control study
Cribb, D. M., Varrone, L., Wallace, R. L., McLure, A., Smith, J. J., Stafford, R. J., Bulach, D., Selvey, L. A., Firestone, S. M., French, N. P., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07553-6 · Cited by 21
Decreased acid suppression therapy overuse after education and medication reconciliation
Gupta, R., Marshall, J. B., Muñoz, J. C., Kottoor, R., Jamal, M. M., & Vega, K. J. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12046 · Cited by 21
Review of medical and surgical management of Clostridium difficile infection
Faris, B., Blackmore, A., & Haboubi, N. Y. (2010) · Techniques in Coloproctology · doi:10.1007/s10151-010-0574-3 · Cited by 21
Choung, R. S., Locke, G. R., Schleck, C. D., Zinsmeister, A. R., & Talley, N. J. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12082 · Cited by 21
Bacterial Infection in Patients with Cirrhosis: Don’t Get Bugged to Death
Cannon, M. D., Martin, P. B., & Carrion, A. F. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05943-6 · Cited by 21
Conventional versus Molecular Methods for the Detection of Clostridium difficile
Carroll, K. C., & Loeffelholz, M. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00700-11 · Cited by 20
Stewart, D. B., & Hegarty, J. P. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.069260-0 · Cited by 20
Kalaitzakis, E., Josefsson, A., Castedal, M., Henfridsson, P., Bengtsson, M., Andersson, B. A., & Bjornsson, E. S. (2013) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.836755 · Cited by 20
Desai, M., Ruan, W. H., Thosani, N. C., Amaris, M. A., Scott, J. S., Saeed, A., Dayyeh, B. K. A., Canto, M. I., Abidi, W. M., Alipour, O., et al. (2024) · VideoGIE · doi:10.1016/j.vgie.2024.10.001 · Cited by 19
Weiss, K., Louie, T., Miller, M. A., Mullane, K. M., Crook, D. W., & Gorbach, S. L. (2015) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2014-000028 · Cited by 19
Exploring the Potential Effect of Polypharmacy on the Hematologic Profiles of Clozapine Patients
Shuman, M. D., Trigoboff, E., Demler, T. L., & Opler, L. A. (2014) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000442937.61575.26 · Cited by 19
Evolving concepts in Clostridium difficile colitis
Diggs, N. G., & Surawicz, C. M. (2009) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0060-0 · Cited by 19
Acute gastroenteritis among children in the developing world
Revelas, A. (2012) · Southern African Journal of Epidemiology and Infection · doi:10.1080/10158782.2012.11441503 · Cited by 19
McCaleb, R. V., Gandhi, A. S., Clark, S. M., & Clemmons, A. B. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016644469 · Cited by 19
MacLaren, R., Kassel, L. E., Kiser, T. H., & Fish, D. N. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.986456 · Cited by 19
Acid Suppression and the Risk of Clostridium difficile Infection
Mezoff, E. A., & Cohen, M. B. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.04.047 · Cited by 19
Pohl, J. F., Patel, R. A., Zobell, J. T., Lin, E., Korgenski, E. K., Crowell, K., MacKay, M. W., Richman, A., Larsen, C., & Chatfield, B. A. (2011) · Gastroenterology Research and Practice · doi:10.1155/2011/345012 · Cited by 18
Talk is Cheap, Often Effective: Symptoms in Infants Often Respond to Non-Pharmacologic Measures
Hassall, E. G. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.10.014 · Cited by 18
Fontán, M. P., Lopes, D. M., Enríquez, A. G., López‐Calviño, B., López–Muñiz, A., Falcón, T. G., & Rodríguez–Carmona, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148806 · Cited by 18
Effects of proton pump inhibitor use on the esophageal microbial community
Tasnim, S., Miller, A. L., Jupiter, D. C., Hamilton, C. F., Reep, G. L., Krill, T. S., Pyles, R. B., & Okereke, I. C. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01460-3 · Cited by 17
Colard‐Thomas, J., Thomas, Q. D., & Viala, M. (2023) · Cancers · doi:10.3390/cancers15082276 · Cited by 18
Do proton pump inhibitors protect against cancer progression in GERD?
Miyashita, T., Shah, F. A., Harmon, J. W., Marti, G. P., Matsui, D., Okamoto, K., Makino, I., Hayashi, H., Oyama, K., Nakagawara, H., et al. (2012) · Surgery Today · doi:10.1007/s00595-012-0395-2 · Cited by 17
Clostridium difficile infection and proton pump inhibitors
Pohl, J. F. (2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328355a3e1 · Cited by 17
Roulet, L., Vernaz, N., Giostra, E., Gasche, Y., & Desmeules, J. A. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2011.12.011 · Cited by 19
Almutairi, H., O’Dwyer, M., McCarron, M., McCallion, P., & Henman, M. C. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2018.05.009 · Cited by 18
Bhat, M., Larocque, M., Amorim, M., Herba, K., Martel, M., de Varennes, B., & Barkun, A. N. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/121836 · Cited by 17
Sánchez-Cuén, J. A., Cabrales, A. B. I., Magaña, G. B., & Peraza‐Garay, F. D. J. (2013) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082013000300003 · Cited by 17
Implementation of a proton pump inhibitor stewardship program
Davis, K. W., Hanners, R. E., & Lockwood, S. M. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160670 · Cited by 17
Ramamoorthy, S. L., Lee, J. K., Mintz, Y., Cullen, J., Savu, M. K., Easter, D. W., Chock, A., Mittal, R., Horgan, S., & Talamini, M. A. (2009) · Surgical Endoscopy · doi:10.1007/s00464-009-0559-3 · Cited by 16
Chan, G. C., Ng, J. K., Chow, K.-M., Cheng, P. M., Law, M.-C., Leung, C. B., Li, P. K.-T., & Szeto, C. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1859-8 · Cited by 16
Juul-Hansen, P., & Rydning, A. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03877.x · Cited by 16
Proton pump inhibitors for upper gastrointestinal bleeding
Kherad, O., Restellini, S., Martel, M., & Barkun, A. N. (2019) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2019.04.002 · Cited by 16
Douwes, R. M., Neto, A. W. G., Eisenga, M. F., Loon, E. V., Schutten, J. C., Gans, R. O. B., Naesens, M., van den Berg, E., Sprangers, B., Berger, S. P., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003140 · Cited by 16
Lai, C.-C., Ji, D.-D., Wu, F., Mu, J., Yang, J.-R., Jiang, D. D.-S., Lin, W.-Y., Chen, W.-T., Yen, M.-Y., Wu, H.-S., et al. (2015) · Journal of Epidemiology · doi:10.2188/jea.je20150061 · Cited by 16
Metadata
- Authors
- Leonard, J., Marshall, J. K., & Moayyedi, P.
- Affiliations
- McMaster University (CA)
- Venue
- The American Journal of Gastroenterology
- Published
- 2007-09
- Volume
- 102
- Issue
- 9
- Pages
- 2047-2056
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2114271048
- Cited by
- 633
- References
- 46
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 22 · 2023: 24 · 2022: 32 · 2021: 35 · 2020: 39 · 2019: 29 · 2018: 35 · 2017: 41 · 2016: 30 · 2015: 28 · 2014: 30 · 2013: 63 · 2012: 55
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
- Keywords
- acid suppression, proton pump inhibitors, H2 receptor antagonists, gastrointestinal infections, Clostridium difficile infection, Salmonella, Campylobacter, Clostridium difficile-associated diarrhea, antisecretory therapy, infection risk, drug safety, Helicobacter pylori, Helicobacter heilmannii
- MeSH terms
- Bacterial Infections, Gastric Acid, Gastrointestinal Diseases, Histamine H2 Antagonists, Humans, Risk Factors, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review